EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment response and survival outcomes of ER-low versus ER-0 HER2-negative breast cancer after neoadjuvant chemotherapy: a multicenter real-world study

Qingwei Wang, Junyi Shen, Songping Lin, Tianzi Hong, Weibin Lian

Frontiers in Oncology · 20.11.2026 · 16

DOI: 10.3389/fonc.2026.1992334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.11.2026. Verfasst von Qingwei Wang und 4 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical significance of ER-low tumors compared with ER-0 tumors in HER2-negative breast cancer remains poorly defined, particularly regarding response to neoadjuvant chemotherapy and survival outcomes. This study aimed to compare the clinical characteristics, treatment response, and survival outcomes between ER-low and ER-0 tumors in a real-world multicenter cohort.

Methods

We conducted a multicenter retrospective cohort study of patients with HER2-negative breast cancer who received neoadjuvant chemotherapy. Patients were categorized according to ER expression as ER-0 or ER-low (1–10%). The primary endpoint was pCR, while disease-free survival (DFS) and breast cancer-specific survival (BCSS) were evaluated as survival outcomes. Multivariable logistic and Cox regression analyses were performed to assess associations between ER status, treatment characteristics, pCR, and clinical outcomes. Propensity score matching (PSM) was used as a sensitivity analysis to compare survival outcomes between ER-0 and ER-low tumors.

Results

Among 1,266 patients, 1,008 had ER-0 and 258 had ER-low tumors. ER-low tumors had a similar likelihood of achieving pCR compared with ER-0 tumors after multivariable adjustment (OR = 0.95, 95% CI: 0.71–1.27; P = 0.726). Platinum-based neoadjuvant chemotherapy was associated with higher odds of pCR in the overall cohort (OR = 1.67, 95% CI: 1.31–2.13; P < 0.001), but not among patients with ER-low tumors (adjusted OR = 1.69, 95% CI: 0.90–3.19; P = 0.104). After a median follow-up of 38 months, DFS and BCSS were comparable between ER-0 and ER-low tumors, both before and after PSM. ER-low status was not independently associated with DFS (adjusted HR = 1.27, 95% CI: 0.88–1.83; P = 0.198) or BCSS (adjusted HR = 1.58, 95% CI: 0.93–2.70; P = 0.090). Platinum-based chemotherapy was not independently associated with improved survival. In contrast, pCR was associated with improved DFS and BCSS in both ER-0 and ER-low tumors, and remained independently prognostic for both outcomes among patients with ER-low tumors.

Conclusion

ER-low and ER-0 tumors showed comparable treatment response and short-term survival outcomes, while pathologic response remained prognostic in ER-low breast cancer.

Zitieren

APA

Wang, Q., Shen, J., Lin, S., Hong, T., & Lian, W. (2026). Treatment response and survival outcomes of ER-low versus ER-0 HER2-negative breast cancer after neoadjuvant chemotherapy: a multicenter real-world study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1992334

Vancouver

Wang Q, Shen J, Lin S, Hong T, Lian W. Treatment response and survival outcomes of ER-low versus ER-0 HER2-negative breast cancer after neoadjuvant chemotherapy: a multicenter real-world study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1992334

BibTeX
@article{Wang2026,
  author = {Wang, Qingwei and Shen, Junyi and Lin, Songping and Hong, Tianzi and Lian, Weibin},
  title = {Treatment response and survival outcomes of ER-low versus ER-0 HER2-negative breast cancer after neoadjuvant chemotherapy: a multicenter real-world study},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1992334}
}
Kostenlos starten →